Skip to content

Safety and Clinical Efficacy of High-Frequency Tidal Peritoneal Dialysis: A Research Study

Safety and Clinical Efficacy of High-Frequency Tidal Peritoneal Dialysis: A Research Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129219
Enrollment
Unknown
Registered
2026-08-01
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal dialysis

Interventions

treatment group:Intervention Name: High-Frequency Tidal Peritoneal Dialysis (TPD) Intervention Medicinal Product: Glucose-containing Peritoneal Dialysis Solution Intervention Device: Automated Periton

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 75 years, diagnosed with stage 5 chronic kidney disease. 2.Under stable maintenance peritoneal dialysis for at least 3 months. 3.Peritoneal transport function and dialysis adequacy assessed within 1 month prior to enrollment, with weekly Kt/V less than 1.7 indicating inadequate dialysis under the current regimen.

Exclusion criteria

Exclusion criteria: 1.Positive serological markers for active infectious diseases including hepatitis B, hepatitis C, HIV and syphilis. 2.Presence of intra-abdominal infection. 3.History of peritonitis within the preceding month. 4.Intraperitoneal tumor metastasis. 5.Severe malnutrition or coagulation disorders. 6.Inability to maintain supine position. 7.Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
electrolytes;glucose;

Secondary

MeasureTime frame
ktv;alpha-smooth muscle actin;Interleukin-6 (IL-6);Type I collagen;Total protein;Creatinine;Monocyte Chemoattractant Protein-1 (MCP-1);E-cadherin;Vascular Endothelial Growth Factor;Albumin;N-terminal pro-B-type natriuretic peptide (NT-proBNP);beta2-microglobulin;Fibronectin;Other uremic toxins;Transforming Growth Factor-beta;Urea;C-reactive protein (CRP);

Countries

China

Contacts

Public ContactLiao Ruoxi

West China Hospital of Sichuan University

103203061@qq.com+86 832 85422341

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026